# Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months

> **NCT02442752** · PHASE1 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Pediatric Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Dexlansoprazole

## Key facts

- **NCT ID:** NCT02442752
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-15
- **Primary completion:** 2025-12-23
- **Final completion:** 2025-12-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn: Business decision (no enrollment)
- **Last updated:** 2020-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442752, "Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02442752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*